🟢 Anixa Biosciences is trading 5.6% up today on continued momentum from cancer therapy trials and a recent patent allowance

Anixa Biosciences is trading 5.6% up at $3.23 as investors focus on the company's ovarian cancer CAR-T/CER-T program and breast cancer vaccine developments.

• The move extends Monday’s rebound, which was previously linked to ongoing clinical trial updates and a recent Canadian patent allowance for its breast cancer vaccine technology.
• Despite general weakness across the biotech sector, the stock is outperforming based on company-specific optimism rather than broad market trends.